US3341417A - Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators - Google Patents
Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators Download PDFInfo
- Publication number
- US3341417A US3341417A US472060A US47206065A US3341417A US 3341417 A US3341417 A US 3341417A US 472060 A US472060 A US 472060A US 47206065 A US47206065 A US 47206065A US 3341417 A US3341417 A US 3341417A
- Authority
- US
- United States
- Prior art keywords
- drug
- ingested
- type
- radio
- opaque
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0404—X-ray contrast preparations containing barium sulfate
Definitions
- the present invention relates to a novel method and means for the diagnosis of an ingested drug, especially of the barbiturate type, and more particularly to the utilization of a radio-opaque or other indicator or marker to indicate the amount and type of an ingested drug by means of an X-ray of a patients abdomen or urinalysis.
- each of these fluids have disadvantages in their analysis. For example, considerable quantities of the barbiturates are lost in the formation of water soluble salts. Such loss also depends on the pH of the solution in the stomach. In blood tests, chromagenes interfere with the identification of assay and, therefore, the chromagenes must be extracted with chloroform. In the urine, the metabolites of barbiturates are also present and identification is difficult because the extract crystallizes and these crystals are not specific.
- An important object of the present invention is the provision of a novel indicator to aid in the differential diagnosis of coma. More specifically, this invention relates to a novel method and means to definitely diagnose the 3,341,417 Patented Sept. 12, 1967 cause of coma as due to ingested drugs through a quick and simple test which is easily performed on the patient in coma, without the attendant disadvantages found in prior diagnostic procedures.
- Another important object of the present invention is the provision of a method for determining the type of an ingested drug, the amount of the ingested drug and the approximate time elapsed since ingestion.
- This method involves the addition to the dosage units of the drug marketed for oral ingestion of a non-toxic, relatively insoluble radio-opaque substance which will be visible upon the taking of an X-ray of the patients abdomen. By observing the shape or configuration of the radioopaque substance, the number or amount of the substance and the position or location of the substance in the gastrointestinal tract, one can readily diagnose these three variables cited above.
- the present invention further comprehends the provision of a relatively insoluble radio-opaque marker or indicator which may be incorporated in a dosage unit of the drug marketed for oral ingestion with the indicator of a distinct shape or design which may be quickly determined and disclosed by X-ray.
- a relatively insoluble radio-opaque marker or indicator which may be incorporated in a dosage unit of the drug marketed for oral ingestion with the indicator of a distinct shape or design which may be quickly determined and disclosed by X-ray.
- various drugs may be identified by a distinctively shaped marker in the dosage unit of that drug.
- knowing the marker utilized in a certain dosage unit such as tablet, pill or capsule, one may diagnose the quantity of the drug taken by the number of markers in the patients abdomen or intestinal tract.
- the present invention also comprehends the provision of a relatively insoluble radio-opaque marker or indicator incorporated in a gelatin capsule containing the drug to be ingested.
- the radio-opaque marker is barium sulfate which is incorporated in the gelatin capsule by mixing a liquid suspension of barium sulfate and a gelatin solution and forming the gelatin capsule with the barium sulfate incorporated therein in a conventional manner.
- the present invention also comprehends the provision of an indicator incorporated into a dosage unit which will appear in the urine of the patient, such as methylene blue and certain other azo dyes of different distinctive colors.
- an indicator incorporated into a dosage unit which will appear in the urine of the patient, such as methylene blue and certain other azo dyes of different distinctive colors.
- the urine of a patient in coma would exhibit the distinctive dye substance.
- This invention relates to differential diagnosis of coma and more particularly to whether coma was induced due to ingested drugs. A doctor is frequently called in to see a patient in coma.
- the differential diagnosis of coma is o ten difiicult because of the various numerous conditions which might cause it, and causes must be ruled out one by one before definitive treatment can be instituted.
- the present invention concerns the incorporation into each dosage unit of the drug a non-toxic, relatively insoluble indicator such as a radio-opaque marker providing a distinctive shape or configuration which would be ingested simultaneously with the drug.
- a patient in coma could then have an ordinary X-ray (fiat plate) of the abdomen and the marker would show up on the X-ray plate to indicate the type of drug, quantity and dosage that had been ingested, and treatment could be immediately instituted.
- the R-l,5,5 group are long duration compounds, the R-5,5 group are of intermediate duration and the thiobarbiturates are of relatively short duration. Most of these compounds are in the sodium salt form at the number 1 position on the ring as follows:
- Pentothal sodium is a thiobarbiturate with R-ethyl and R'CHaCH2CHzCH.
- barbiturate is phenobarbital which is in the R-5,5' group with R-ethyl and R'-phenyl. Although there are three groupings for the barbiturates, their treatment is substantially identical. Treatment involves the persistent administration of central nervous system stimulants (stimulant analeptics), such as picrotoxin, pentylene-tetrazol, nikethamide or bemegride, various supportive procedures, and artificial respiration or oxygen if necessary.
- central nervous system stimulants such as picrotoxin, pentylene-tetrazol, nikethamide or bemegride
- radio-opaque indicators which are contemplated for use in the dosage units marketed for oral ingestion.
- One such indicator is a treated insoluble cord or thread which is radio-opaque, which may be incorporated in a standard size gelatin capsule.
- Dosages of drugs such as barbiturates are generally standardized quantities.
- adding a small section of a cord of a radio-opaque material to the contents of each unit having a known dosage will indicate that drug and quantity if shown on an X-ray plate. If there are several different dosage quantities for the drug, the radio-opaque cord marker will be distinctive for each dosage level.
- one dosage quantity would have a straight cord in the unit or capsule, a different dosage would have a cord knotted at short intervals, a third dosage could have a cord which has a coiled configuration and a fourth dosage could be a complete circle of the radio-opaque material.
- a cord is formed of polyvinyl chloride and barium sulfate; the barium sulfate being a commonly used radio-opaque material.
- the stainless steel member may take a number of shapes which would be easily recognizable upon an X-ray plate, such as a sphere or ball, a square or polygonal shape, an ellipsoid, a star, etc.
- a third type of radio-opaque marker or indicator is the utilization of barium sulfate incorporated in the capsule body holding the drug to be ingested.
- a liquid suspension of barium sulfate and gelatin in water is mixed together and gelatin capsules are formed with the barium sulfate incorporated in the gelatin capsule wall; the capsules being formed in a conventional manner.
- the capsules will show up on an X-ray plate in the distinctive shape of the capsule due to the barium sulfate, and the barium sulfate will still be clearly seen on an X-ray even where the capsule has completely dissolved.
- the distinctive marker could also be formed of a radio-opaque plastic of a distinctive shape or configuration, either two or three dimensional, which may be incorporated in the drug in the pill or capsule, or the plastic marker may be incorporated in the wall of the gelatin capsule. Also, rather than the use of barium sulfate, a radio-opaque ink may be utilized to provide a distinctive marking on the wall of the capsule.
- a fourth type of radio-opaque marker involves the use of a radio-opaque plastic which is extruded into a hollow tube having a distinctive cross section.
- a radio-opaque plastic would be a polyvinyl chloride plastic impregnated with barium sulfate.
- the hollow interior of the extruded tubing may have a variety of distinctive shapes or peripheries only limited by the complexity of the extrusion die.
- the barbiturate or other medicine is inserted into the hollow tubing as a powder or in a suspension and solidified to provide a solid core in the tube. Then the tubing is sliced transversely to provide the individual dosage unit and coated with an ultimate candy coating that dissolves in the stomach.
- the plastic tubing will not dissolve and thus will show up on an X-ray plate. Such a plastic would not be toxic to the individual.
- radio-opaque markers may be advantageously applied to other drugs which may produce coma or whenever or wherever it would be deemed expedient for medical intelligence to determine objectively time of ingestion and dosage.
- the varying configurations of the markers could differentiate between drugs as well as differentiating between dosage levels.
- Another type of indicator which may be incorporated in a solid dosage unit of a drug marketed for oral ingestion would be the use of certain azo dyes of different colors, such as methylene blue, which would appear in the urine of the patient. Although the patient is in a comatose condition, the patient would be catheterized and the urine removed would exhibit the dye substance found in the drug.
- Various types of drugs capable of causing coma would contain various easily identifiable azo dye colors, and this indicator would not be limited to solid dosage units but could also be incorporated in liquids, solutions or elixirs.
- a doctor can tell by the number, configuration and location of a marker on an X-ray plate the type of drug, the dosage and number of dosage units ingested, and the approximate time of ingestion. These factors will determine the treatment to be followed and the degree of intensity of treatment.
- the drugs are generally identified as dosage units marketed for oral ingestion and it is intended such shall include capsules, pills or tablets incorporating the drug therein in a standard dosage used for treatment purposes.
- a method of determining durg poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatose subject which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of drug and a distinctively shaped radiopaque marker identifying that specific amount and type of drug, in order to thereby identify such markers present.
- a method of determining drug poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatose subject which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral capsules, each containing therein a specific amount and type of drug and a specific type of distinctively configured radiopaque material incorporated in the capsule wall identifying that specific amount and type of drug, in order to thereby identify such markers present.
- a method of determining drug poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatos subject which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral capsules, each containing therein a specific amount and type of drug and a specific type of distinctive confiugred shaped radiopaque marker identifying that specific amount and type of drug, in order to thereby identify such markers present.
- a method of determining barbiturate poisoning by in vivo roentgenographic identification of ingested peroral dosage units of barbiturate drugs in a comatose subject which comprises roentgenographing the gastrointestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of distinctively configured shaped radiopaque marker identifying that specific amount and type of barbiturate drug, in order to thereby identify such markers present.
- a method of determining barbiturate poisoning by in vivo roentgenographic identification of ingested peroral dosage units of barbiturate drugs in a comatose subject which comprises roentgenographing the gastrointestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of distinctively configured shaped radiopaque marker embedded therein identifying that specific amount and type of barbiturate drug, in order to thereby identify such markers present.
- a method of determining drug poisoning by identification of azo dye in the urine of a comatose subject which comprises catheterizing urine from a comatoes subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of drug and a specific type of azo dye distinctively identifying that specific amount and type of drug, in order to thereby identify the type of azo dye present.
- a method of determining barbiturate poisoning by identification of azo dye in the urine of a comatose subject which comprises catheterizing urine from a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of azo dye distinctively identifying that specific amount and type of barbiturate drug, in order to thereby identfy the type of azo dye present.
Description
United States Patent 3 341,417 METHOD OF AND MEANS FOR DIAGNOSIS OF INGESTED DRUGS WITH RADIO-OPAQUE AND OTHER INDICATORS Edwin S. Sinaiko, 5555 S. Everett Ave., Chicago, II]. 60627 No Drawing. Filed July 14, 1965, Ser. No. 472,060 Claims. (Cl. 167-845) This application is a continuation-in-part of my copending application Ser. No. 271,887, filed Apr. 10, 1963, now abandoned.
The present invention relates to a novel method and means for the diagnosis of an ingested drug, especially of the barbiturate type, and more particularly to the utilization of a radio-opaque or other indicator or marker to indicate the amount and type of an ingested drug by means of an X-ray of a patients abdomen or urinalysis.
Posioning by barbiturates often involves death after a long period in a coma unless suitable treatment is performed to revive the patient. Many times treatment must be delayed while laboratory tests are performed to determine if drugs have been taken into the system which would result in a coma. Thus, the need for immediate identification, determination of dosage, and determination of the period of time which has elapsed since ingestion is a very important one in the differential diagnosis of coma due to ingested drugs.
The large number of cases of barbiturate poisoning due to heavy sale of these drugs, with or without prescriptions, has focused attention upon the necessity of identifying the barbiturates and their metabolites. According to known texts on toxicology the methods of identification of the barbiturates are many and slow, and none are completely satisfactory. To successfully identify such compounds, the group must be isolated from the viscera. The common fluids used for analysis to determine if drugs are involved are stomach washes, blood and urine, and the quickest extraction procedures for all these fluids is a direct extraction using ether of chloroform as the organic solvent.
However, each of these fluids have disadvantages in their analysis. For example, considerable quantities of the barbiturates are lost in the formation of water soluble salts. Such loss also depends on the pH of the solution in the stomach. In blood tests, chromagenes interfere with the identification of assay and, therefore, the chromagenes must be extracted with chloroform. In the urine, the metabolites of barbiturates are also present and identification is difficult because the extract crystallizes and these crystals are not specific.
Polymorphic forms of many barbiturates exist, and X-ray defraction techniques are utilized for identification, and also different solvent techniques and micro melting points are useful. A more recent technique is the purification using chromatography and counter-current techniques followed by identification. Other routine methods of analysis are X-ray diffraction, infra-red spectrophotometry and assay by means of ultra-violet spectrophotometry. However, all of these analysis techniques require considerable time for proper determination and, in the meantime, valuable time is lost before proper treatment may be prescribed.
An important object of the present invention is the provision of a novel indicator to aid in the differential diagnosis of coma. More specifically, this invention relates to a novel method and means to definitely diagnose the 3,341,417 Patented Sept. 12, 1967 cause of coma as due to ingested drugs through a quick and simple test which is easily performed on the patient in coma, without the attendant disadvantages found in prior diagnostic procedures.
Another important object of the present invention is the provision of a method for determining the type of an ingested drug, the amount of the ingested drug and the approximate time elapsed since ingestion. This method involves the addition to the dosage units of the drug marketed for oral ingestion of a non-toxic, relatively insoluble radio-opaque substance which will be visible upon the taking of an X-ray of the patients abdomen. By observing the shape or configuration of the radioopaque substance, the number or amount of the substance and the position or location of the substance in the gastrointestinal tract, one can readily diagnose these three variables cited above.
The present invention further comprehends the provision of a relatively insoluble radio-opaque marker or indicator which may be incorporated in a dosage unit of the drug marketed for oral ingestion with the indicator of a distinct shape or design which may be quickly determined and disclosed by X-ray. Thus, various drugs may be identified by a distinctively shaped marker in the dosage unit of that drug. Further, knowing the marker utilized in a certain dosage unit such as tablet, pill or capsule, one may diagnose the quantity of the drug taken by the number of markers in the patients abdomen or intestinal tract.
The present invention also comprehends the provision of a relatively insoluble radio-opaque marker or indicator incorporated in a gelatin capsule containing the drug to be ingested. The radio-opaque marker is barium sulfate which is incorporated in the gelatin capsule by mixing a liquid suspension of barium sulfate and a gelatin solution and forming the gelatin capsule with the barium sulfate incorporated therein in a conventional manner.
The present invention also comprehends the provision of an indicator incorporated into a dosage unit which will appear in the urine of the patient, such as methylene blue and certain other azo dyes of different distinctive colors. Thus, the urine of a patient in coma would exhibit the distinctive dye substance.
Further objects and advantages of my invention should be apparent to those skilledin the art from the following description.
This invention relates to differential diagnosis of coma and more particularly to whether coma was induced due to ingested drugs. A doctor is frequently called in to see a patient in coma. The differential diagnosis of coma is o ten difiicult because of the various numerous conditions which might cause it, and causes must be ruled out one by one before definitive treatment can be instituted.
Since barbiturate poisoning is not an uncommon 0ccurrence, an immediate method of determining its ingestion would considerably shorten the time required for diagnosis. The present invention concerns the incorporation into each dosage unit of the drug a non-toxic, relatively insoluble indicator such as a radio-opaque marker providing a distinctive shape or configuration which would be ingested simultaneously with the drug. A patient in coma could then have an ordinary X-ray (fiat plate) of the abdomen and the marker would show up on the X-ray plate to indicate the type of drug, quantity and dosage that had been ingested, and treatment could be immediately instituted.
Barbiturates are normally divided into three chemical groups having varying times of duration of effectiveness:
The R-l,5,5 group are long duration compounds, the R-5,5 group are of intermediate duration and the thiobarbiturates are of relatively short duration. Most of these compounds are in the sodium salt form at the number 1 position on the ring as follows:
Pentothal sodium is a thiobarbiturate with R-ethyl and R'CHaCH2CHzCH.
Another well known barbiturate is phenobarbital which is in the R-5,5' group with R-ethyl and R'-phenyl. Although there are three groupings for the barbiturates, their treatment is substantially identical. Treatment involves the persistent administration of central nervous system stimulants (stimulant analeptics), such as picrotoxin, pentylene-tetrazol, nikethamide or bemegride, various supportive procedures, and artificial respiration or oxygen if necessary.
Since treatment for barbiturate poisoning is generally the same for all types of barbiturates, the problems are resolved to the dosage and the time when the drug was ingested. Although the effect of barbiturates in toxic doses on the mobility of the gastrointestinal tract is to slow it and produce stasis, knowing where the drug lies spatially in the tract may be an important advantage in treating the patient. The location of the radio-opaque indicator in the X-ray plate would give a clue as to where in the intestine the drugs (if not completely absorbed) were, and some indication in the time needed to reach that level; therefore, the approximate time when the drug was taken.
Now referring specifically to the radio-opaque indicators which are contemplated for use in the dosage units marketed for oral ingestion. One such indicator is a treated insoluble cord or thread which is radio-opaque, which may be incorporated in a standard size gelatin capsule. Dosages of drugs such as barbiturates are generally standardized quantities. Thus, adding a small section of a cord of a radio-opaque material to the contents of each unit having a known dosage will indicate that drug and quantity if shown on an X-ray plate. If there are several different dosage quantities for the drug, the radio-opaque cord marker will be distinctive for each dosage level. For example, one dosage quantity would have a straight cord in the unit or capsule, a different dosage would have a cord knotted at short intervals, a third dosage could have a cord which has a coiled configuration and a fourth dosage could be a complete circle of the radio-opaque material. Such a cord is formed of polyvinyl chloride and barium sulfate; the barium sulfate being a commonly used radio-opaque material.
Another type of marker which may be incorporated in a dosage unit of the drug marketed for oral ingestion would be a small ball of stainless steel or like material which would be unaifected by the stomach acids or other fluids in the body and which would be nontoxic so as not to be injurious to the health of the person. To differentiate between different dosage levels, the stainless steel member may take a number of shapes which would be easily recognizable upon an X-ray plate, such as a sphere or ball, a square or polygonal shape, an ellipsoid, a star, etc.
A third type of radio-opaque marker or indicator is the utilization of barium sulfate incorporated in the capsule body holding the drug to be ingested. A liquid suspension of barium sulfate and gelatin in water is mixed together and gelatin capsules are formed with the barium sulfate incorporated in the gelatin capsule wall; the capsules being formed in a conventional manner. The capsules will show up on an X-ray plate in the distinctive shape of the capsule due to the barium sulfate, and the barium sulfate will still be clearly seen on an X-ray even where the capsule has completely dissolved.
The distinctive marker could also be formed of a radio-opaque plastic of a distinctive shape or configuration, either two or three dimensional, which may be incorporated in the drug in the pill or capsule, or the plastic marker may be incorporated in the wall of the gelatin capsule. Also, rather than the use of barium sulfate, a radio-opaque ink may be utilized to provide a distinctive marking on the wall of the capsule.
A fourth type of radio-opaque marker involves the use of a radio-opaque plastic which is extruded into a hollow tube having a distinctive cross section. Such a radio-opaque plastic would be a polyvinyl chloride plastic impregnated with barium sulfate. The hollow interior of the extruded tubing may have a variety of distinctive shapes or peripheries only limited by the complexity of the extrusion die. The barbiturate or other medicine is inserted into the hollow tubing as a powder or in a suspension and solidified to provide a solid core in the tube. Then the tubing is sliced transversely to provide the individual dosage unit and coated with an ultimate candy coating that dissolves in the stomach. The plastic tubing will not dissolve and thus will show up on an X-ray plate. Such a plastic would not be toxic to the individual.
Although the description of this invention has dealt primary with barbiturate poisoning which is presently the most common source of poisoning producing coma, this concept of radio-opaque markers may be advantageously applied to other drugs which may produce coma or whenever or wherever it would be deemed expedient for medical intelligence to determine objectively time of ingestion and dosage. The varying configurations of the markers could differentiate between drugs as well as differentiating between dosage levels.
Another type of indicator which may be incorporated in a solid dosage unit of a drug marketed for oral ingestion would be the use of certain azo dyes of different colors, such as methylene blue, which would appear in the urine of the patient. Although the patient is in a comatose condition, the patient would be catheterized and the urine removed would exhibit the dye substance found in the drug. Various types of drugs capable of causing coma would contain various easily identifiable azo dye colors, and this indicator would not be limited to solid dosage units but could also be incorporated in liquids, solutions or elixirs.
By the use of the markers in the drugs to be ingested or in the body of the capsule or pill, a doctor can tell by the number, configuration and location of a marker on an X-ray plate the type of drug, the dosage and number of dosage units ingested, and the approximate time of ingestion. These factors will determine the treatment to be followed and the degree of intensity of treatment.
In the foregoing description, the drugs are generally identified as dosage units marketed for oral ingestion and it is intended such shall include capsules, pills or tablets incorporating the drug therein in a standard dosage used for treatment purposes.
Having thus disclosed the invention, I claim:
1. A method of determining durg poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatose subject, which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of drug and a distinctively shaped radiopaque marker identifying that specific amount and type of drug, in order to thereby identify such markers present.
2 A method of determining drug poisoning as set forth in claim 1, in which the number of radiopaque markers indicated on the roentgenograph indicates the number of dosage units ingested and their position in the gastro-intestinal tract indicates the approximate time of ingestion.
3. A method of determining drug poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatose subject, which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral capsules, each containing therein a specific amount and type of drug and a specific type of distinctively configured radiopaque material incorporated in the capsule wall identifying that specific amount and type of drug, in order to thereby identify such markers present.
4. A method of determining drug poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatos subject, which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral capsules, each containing therein a specific amount and type of drug and a specific type of distinctive confiugred shaped radiopaque marker identifying that specific amount and type of drug, in order to thereby identify such markers present.
5. A method of determining drug poisoning as set forth in claim 4, in which the radiopaque marker is distinctively shaped to indicate the dosage level of the drug.
6. A method of determining barbiturate poisoning by in vivo roentgenographic identification of ingested peroral dosage units of barbiturate drugs in a comatose subject, which comprises roentgenographing the gastrointestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of distinctively configured shaped radiopaque marker identifying that specific amount and type of barbiturate drug, in order to thereby identify such markers present.
7. A method of determining barbiturate poisoning by in vivo roentgenographic identification of ingested peroral dosage units of barbiturate drugs in a comatose subject, which comprises roentgenographing the gastrointestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of distinctively configured shaped radiopaque marker embedded therein identifying that specific amount and type of barbiturate drug, in order to thereby identify such markers present.
8. A method of determining barbiturate poisoning as set forth in claim 7, in which varying dosages of the barbiturate drug are indicated by different configurations of said marker, and the number and position of the markers indicate the number of dosage units ingested and the approximate time of ingestion.
9. A method of determining drug poisoning by identification of azo dye in the urine of a comatose subject, which comprises catheterizing urine from a comatoes subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of drug and a specific type of azo dye distinctively identifying that specific amount and type of drug, in order to thereby identify the type of azo dye present.
10. A method of determining barbiturate poisoning by identification of azo dye in the urine of a comatose subject, which comprises catheterizing urine from a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of azo dye distinctively identifying that specific amount and type of barbiturate drug, in order to thereby identfy the type of azo dye present.
References Cited UNITED STATES PATENTS 2,072,302 3/1937 Herrmann et al. 128335.5 2,330,718 9/1943 Kallmann 283-8 3,146,169 8/1964 Stephenson et al 16782 FOREIGN PATENTS 866,924 5/1961 Great Britain. 936,386 9/1963 Great Britain. 972,128 10/ 1964 Great Britain.
OTHER REFERENCES Collier Lancet, pages 473 to 475, Mar. 3, 1962.
Dewey et al.: Nature 181: 1367 to 1371, May 17, 1958.
Feinblatt et al.: New Eng. J. Med. 254, 290 to 943, May 17, 1956.
Hammerness et al.: I. A. Ph. 358, June 1954.
Hastings: Pharm. I. 184 1960.
Skerman et al.:
November 1959.
Thompson et al.: J. A. Ph. (1945). 19Zlhitney: Brit. Med. J. (5165), pages 50 to 51, Jan. 2,
LEWIS GOTTS, Primary Examiner. S. K. ROSE, Assistant Examiner.
A. (Sci. Ed.) 43, 357 to (5020), 45 to 47, Jan. 16,
Am. J. Vet. Res. 20, 977 to 984,
A. (Sci. Ed.) 34, to 138
Claims (1)
1. A METHOD OF DETERMINING DURG POISONING BY IN VIVO ROENTGENOGRAPHIC IDENTIFICATION OF INGESTED PERORAL DOSAGE UNITS OF DRUGS IN A COMATOSE SUBJECT, WHICH OMCPRISES ROENTGENOGRAPHING THE GASTRO-INTESTINAL TRACT OF A COMATOSE SUBJECT WHO HAS PREVIOUSLY INGESTED PERORAL DOSAGE UNITS, EACH CONTAINING THEREIN A SPECIFIC AMOUNT AND TYPE OF DRUG AND A DISTINCTIVELY SHAPED RADIOPAQUE MARKER IDENTIFYING THAT SPECIFIC AMOUNT AND TYPE OF DRUG, IN ORDER TO THEREBY IDENTIFY SUCH MARKERS PRESENT.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US472060A US3341417A (en) | 1965-07-14 | 1965-07-14 | Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US472060A US3341417A (en) | 1965-07-14 | 1965-07-14 | Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators |
Publications (1)
Publication Number | Publication Date |
---|---|
US3341417A true US3341417A (en) | 1967-09-12 |
Family
ID=23874040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US472060A Expired - Lifetime US3341417A (en) | 1965-07-14 | 1965-07-14 | Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators |
Country Status (1)
Country | Link |
---|---|
US (1) | US3341417A (en) |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3818229A (en) * | 1970-12-21 | 1974-06-18 | Univ Illinois | Radiopaque agents comprising brominated perfluorocarbons |
US4193985A (en) * | 1977-03-30 | 1980-03-18 | A/S Alfred Benzon | Multiple-units drug dose |
US4339463A (en) * | 1979-08-24 | 1982-07-13 | Shionogi & Co., Ltd. | Enterosoluble hard-capsulated medicaments |
US4863470A (en) * | 1985-03-19 | 1989-09-05 | Medical Engineering Corporation | Identification marker for a breast prosthesis |
US4900557A (en) * | 1984-08-30 | 1990-02-13 | Troponwerke Gmbh & Co. Kg | Pellet formulation |
US5368027A (en) * | 1992-04-23 | 1994-11-29 | Avl Medical Instruments Ag | Sensor arrangement for direct or indirect optical determination of physical or chemical properties |
US5460798A (en) * | 1992-06-22 | 1995-10-24 | Barnett; Patrick A. | System for determining the quantity and identity of material ingested by user |
US6347241B2 (en) * | 1999-02-02 | 2002-02-12 | Senorx, Inc. | Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it |
US6497706B1 (en) | 1998-03-03 | 2002-12-24 | Senorx, Inc. | Biopsy device and method of use |
US6638234B2 (en) | 1998-03-03 | 2003-10-28 | Senorx, Inc. | Sentinel node location and biopsy |
US20030233101A1 (en) * | 2002-06-17 | 2003-12-18 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US6679851B2 (en) | 1998-09-01 | 2004-01-20 | Senorx, Inc. | Tissue accessing and anchoring device and method |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US6758848B2 (en) | 1998-03-03 | 2004-07-06 | Senorx, Inc. | Apparatus and method for accessing a body site |
US20040236211A1 (en) * | 2003-05-23 | 2004-11-25 | Senorx, Inc. | Marker or filler forming fluid |
US20040236213A1 (en) * | 2003-05-23 | 2004-11-25 | Senorx, Inc. | Marker delivery device with releasable plug |
US6875182B2 (en) | 1998-03-03 | 2005-04-05 | Senorx, Inc. | Electrosurgical specimen-collection system |
US20050119562A1 (en) * | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US20050143656A1 (en) * | 1999-02-02 | 2005-06-30 | Senorx, Inc. | Cavity-filling biopsy site markers |
US20060084865A1 (en) * | 1999-02-02 | 2006-04-20 | Burbank Fred H | Imageable biopsy site marker |
US20060241411A1 (en) * | 2005-04-20 | 2006-10-26 | Inrad, Inc. | Marking device with retracable cannula |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
US20080108949A1 (en) * | 2006-11-08 | 2008-05-08 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US7377902B2 (en) | 1998-04-08 | 2008-05-27 | Senorx, Inc. | Biopsy anchor device with cutter |
US20080140025A1 (en) * | 2005-03-04 | 2008-06-12 | C. R. Bard, Inc. | Access port identification systems and methods |
US20090156928A1 (en) * | 2007-11-07 | 2009-06-18 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US20090171198A1 (en) * | 2006-08-04 | 2009-07-02 | Jones Michael L | Powdered marker |
US7572236B2 (en) | 2005-08-05 | 2009-08-11 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US20100010341A1 (en) * | 2006-12-18 | 2010-01-14 | Talpade Dnyanesh A | Biopsy Marker with In Situ-Generated Imaging Properties |
US20100030072A1 (en) * | 2006-12-12 | 2010-02-04 | Casanova R Michael | Multiple Imaging Mode Tissue Marker |
US20100082102A1 (en) * | 2008-09-23 | 2010-04-01 | Senorx, Inc. | Porous bioabsorbable implant |
US20100268165A1 (en) * | 2005-03-04 | 2010-10-21 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US20100298698A1 (en) * | 2000-11-20 | 2010-11-25 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US20100298696A1 (en) * | 2003-11-17 | 2010-11-25 | Bard Peripheral Vascular, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US20100331668A1 (en) * | 2008-01-31 | 2010-12-30 | Ranpura Himanshu M | Biopsy Tissue Marker |
US20110009828A1 (en) * | 2009-07-07 | 2011-01-13 | C.R.Bard, Inc. | Extensible internal bolster for a medical device |
US20110028836A1 (en) * | 2008-12-30 | 2011-02-03 | Himanshu Ranpura | Marker delivery device for tissue marker placement |
US20110082547A1 (en) * | 1997-10-10 | 2011-04-07 | Senorx, Inc. | Tissue marking implant |
US20110118677A1 (en) * | 2009-11-17 | 2011-05-19 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US7947022B2 (en) | 2005-03-04 | 2011-05-24 | C. R. Bard, Inc. | Access port identification systems and methods |
US20110166448A1 (en) * | 1999-02-02 | 2011-07-07 | Jones Michael L | Marker delivery device with releasable plug |
US20110184449A1 (en) * | 2006-08-04 | 2011-07-28 | Senorx, Inc. | Marker delivery device with obturator |
US20110184280A1 (en) * | 1999-02-02 | 2011-07-28 | Jones Michael L | Intracorporeal marker and marker delivery device |
US8021324B2 (en) | 2007-07-19 | 2011-09-20 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US8025639B2 (en) | 2005-04-27 | 2011-09-27 | C. R. Bard, Inc. | Methods of power injecting a fluid through an access port |
US8177762B2 (en) | 1998-12-07 | 2012-05-15 | C. R. Bard, Inc. | Septum including at least one identifiable feature, access ports including same, and related methods |
US8202259B2 (en) | 2005-03-04 | 2012-06-19 | C. R. Bard, Inc. | Systems and methods for identifying an access port |
US8257325B2 (en) | 2007-06-20 | 2012-09-04 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US8317725B2 (en) | 2005-08-05 | 2012-11-27 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US8343071B2 (en) | 2004-12-16 | 2013-01-01 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
USD676955S1 (en) | 2010-12-30 | 2013-02-26 | C. R. Bard, Inc. | Implantable access port |
US8437834B2 (en) | 2006-10-23 | 2013-05-07 | C. R. Bard, Inc. | Breast marker |
USD682416S1 (en) | 2010-12-30 | 2013-05-14 | C. R. Bard, Inc. | Implantable access port |
US8486028B2 (en) | 2005-10-07 | 2013-07-16 | Bard Peripheral Vascular, Inc. | Tissue marking apparatus having drug-eluting tissue marker |
US8579931B2 (en) | 1999-06-17 | 2013-11-12 | Bard Peripheral Vascular, Inc. | Apparatus for the percutaneous marking of a lesion |
US8641640B2 (en) | 2005-05-23 | 2014-02-04 | Senorx, Inc. | Tissue cutting member for a biopsy device |
US8641676B2 (en) | 2005-04-27 | 2014-02-04 | C. R. Bard, Inc. | Infusion apparatuses and methods of use |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US9149341B2 (en) | 1999-02-02 | 2015-10-06 | Senorx, Inc | Deployment of polysaccharide markers for treating a site within a patient |
US9265912B2 (en) | 2006-11-08 | 2016-02-23 | C. R. Bard, Inc. | Indicia informative of characteristics of insertable medical devices |
US9408592B2 (en) | 2003-12-23 | 2016-08-09 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
US9474888B2 (en) | 2005-03-04 | 2016-10-25 | C. R. Bard, Inc. | Implantable access port including a sandwiched radiopaque insert |
US9610432B2 (en) | 2007-07-19 | 2017-04-04 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
US9927448B1 (en) * | 2017-03-22 | 2018-03-27 | David R. Hall | Method of measuring food dyes in bodily waste to identify and quantify drug consumption |
US9950150B2 (en) | 2009-10-16 | 2018-04-24 | Smiths Medical Asd, Inc. | Portal with septum embedded indicia |
US10145856B2 (en) * | 2017-03-22 | 2018-12-04 | Hall Labs, Llc | Drug tracking system including food dyes detectable in bodily waste |
US10307581B2 (en) | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
US11890443B2 (en) | 2008-11-13 | 2024-02-06 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2072302A (en) * | 1931-03-10 | 1937-03-02 | Chemische Forschungs Gmbh | Polymerized vinyl alcohol articles and processes of making same |
US2330718A (en) * | 1942-01-05 | 1943-09-28 | Heinz E Kallmann | Bank note |
GB866924A (en) * | 1956-11-05 | 1961-05-03 | Commw Scient Ind Res Org | Improved means for supplying small amounts of nutritional or therapeutic substances to ruminants |
GB936386A (en) * | 1959-01-16 | 1963-09-11 | Wellcome Found | Pellets for supplying biologically active substances to ruminants |
US3146169A (en) * | 1960-01-21 | 1964-08-25 | Burroughs Wellcome Co | Pharmaceutical formulations and their manufacture |
-
1965
- 1965-07-14 US US472060A patent/US3341417A/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2072302A (en) * | 1931-03-10 | 1937-03-02 | Chemische Forschungs Gmbh | Polymerized vinyl alcohol articles and processes of making same |
US2330718A (en) * | 1942-01-05 | 1943-09-28 | Heinz E Kallmann | Bank note |
GB866924A (en) * | 1956-11-05 | 1961-05-03 | Commw Scient Ind Res Org | Improved means for supplying small amounts of nutritional or therapeutic substances to ruminants |
GB936386A (en) * | 1959-01-16 | 1963-09-11 | Wellcome Found | Pellets for supplying biologically active substances to ruminants |
US3146169A (en) * | 1960-01-21 | 1964-08-25 | Burroughs Wellcome Co | Pharmaceutical formulations and their manufacture |
GB972128A (en) * | 1960-01-21 | 1964-10-07 | Wellcome Found | Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets |
Cited By (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3818229A (en) * | 1970-12-21 | 1974-06-18 | Univ Illinois | Radiopaque agents comprising brominated perfluorocarbons |
US4193985A (en) * | 1977-03-30 | 1980-03-18 | A/S Alfred Benzon | Multiple-units drug dose |
US4339463A (en) * | 1979-08-24 | 1982-07-13 | Shionogi & Co., Ltd. | Enterosoluble hard-capsulated medicaments |
US4397835A (en) * | 1979-08-24 | 1983-08-09 | Shionogi & Co., Ltd. | Enterosoluble hard-capsulated medicaments |
US4900557A (en) * | 1984-08-30 | 1990-02-13 | Troponwerke Gmbh & Co. Kg | Pellet formulation |
US4863470A (en) * | 1985-03-19 | 1989-09-05 | Medical Engineering Corporation | Identification marker for a breast prosthesis |
US5368027A (en) * | 1992-04-23 | 1994-11-29 | Avl Medical Instruments Ag | Sensor arrangement for direct or indirect optical determination of physical or chemical properties |
US5460798A (en) * | 1992-06-22 | 1995-10-24 | Barnett; Patrick A. | System for determining the quantity and identity of material ingested by user |
US8157862B2 (en) | 1997-10-10 | 2012-04-17 | Senorx, Inc. | Tissue marking implant |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US9039763B2 (en) | 1997-10-10 | 2015-05-26 | Senorx, Inc. | Tissue marking implant |
US20110082547A1 (en) * | 1997-10-10 | 2011-04-07 | Senorx, Inc. | Tissue marking implant |
US6638234B2 (en) | 1998-03-03 | 2003-10-28 | Senorx, Inc. | Sentinel node location and biopsy |
US6716179B2 (en) | 1998-03-03 | 2004-04-06 | Senorx, Inc. | Sentinel node location and biopsy |
US6758848B2 (en) | 1998-03-03 | 2004-07-06 | Senorx, Inc. | Apparatus and method for accessing a body site |
US8147487B2 (en) | 1998-03-03 | 2012-04-03 | Senorx, Inc. | Apparatus and method for accessing a body site |
US6497706B1 (en) | 1998-03-03 | 2002-12-24 | Senorx, Inc. | Biopsy device and method of use |
US7229439B2 (en) | 1998-03-03 | 2007-06-12 | Senorx, Inc. | Apparatus and method for accessing a body site |
US6875182B2 (en) | 1998-03-03 | 2005-04-05 | Senorx, Inc. | Electrosurgical specimen-collection system |
US7377902B2 (en) | 1998-04-08 | 2008-05-27 | Senorx, Inc. | Biopsy anchor device with cutter |
US6679851B2 (en) | 1998-09-01 | 2004-01-20 | Senorx, Inc. | Tissue accessing and anchoring device and method |
US7282034B2 (en) | 1998-09-01 | 2007-10-16 | Senorx, Inc. | Tissue accessing and anchoring device and method |
US8177762B2 (en) | 1998-12-07 | 2012-05-15 | C. R. Bard, Inc. | Septum including at least one identifiable feature, access ports including same, and related methods |
US8608713B2 (en) | 1998-12-07 | 2013-12-17 | C. R. Bard, Inc. | Septum feature for identification of an access port |
US20060155190A1 (en) * | 1999-02-02 | 2006-07-13 | Senorx, Inc. | Imageable biopsy site marker |
US7565191B2 (en) | 1999-02-02 | 2009-07-21 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US6993375B2 (en) | 1999-02-02 | 2006-01-31 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US6996433B2 (en) | 1999-02-02 | 2006-02-07 | Senorx, Inc. | Imageable biopsy site marker |
US20060036165A1 (en) * | 1999-02-02 | 2006-02-16 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US20060084865A1 (en) * | 1999-02-02 | 2006-04-20 | Burbank Fred H | Imageable biopsy site marker |
US7047063B2 (en) * | 1999-02-02 | 2006-05-16 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US20060122503A1 (en) * | 1999-02-02 | 2006-06-08 | Senorx, Inc. | Imageable biopsy site marker |
US9649093B2 (en) | 1999-02-02 | 2017-05-16 | Senorx, Inc. | Cavity-filling biopsy site markers |
US20110184280A1 (en) * | 1999-02-02 | 2011-07-28 | Jones Michael L | Intracorporeal marker and marker delivery device |
US20050063908A1 (en) * | 1999-02-02 | 2005-03-24 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US9861294B2 (en) | 1999-02-02 | 2018-01-09 | Senorx, Inc. | Marker delivery device with releasable plug |
US9237937B2 (en) | 1999-02-02 | 2016-01-19 | Senorx, Inc. | Cavity-filling biopsy site markers |
US9149341B2 (en) | 1999-02-02 | 2015-10-06 | Senorx, Inc | Deployment of polysaccharide markers for treating a site within a patient |
US9044162B2 (en) | 1999-02-02 | 2015-06-02 | Senorx, Inc. | Marker delivery device with releasable plug |
US10172674B2 (en) | 1999-02-02 | 2019-01-08 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US20040193044A1 (en) * | 1999-02-02 | 2004-09-30 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US20090131825A1 (en) * | 1999-02-02 | 2009-05-21 | Senorx, Inc. | Imageable biopsy site marker |
US8965486B2 (en) | 1999-02-02 | 2015-02-24 | Senorx, Inc. | Cavity filling biopsy site markers |
US20110166448A1 (en) * | 1999-02-02 | 2011-07-07 | Jones Michael L | Marker delivery device with releasable plug |
US6347241B2 (en) * | 1999-02-02 | 2002-02-12 | Senorx, Inc. | Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it |
US20050143656A1 (en) * | 1999-02-02 | 2005-06-30 | Senorx, Inc. | Cavity-filling biopsy site markers |
US6662041B2 (en) * | 1999-02-02 | 2003-12-09 | Senorx, Inc. | Imageable biopsy site marker |
US20040116806A1 (en) * | 1999-02-02 | 2004-06-17 | Senorx, Inc. | Biopsy site marker and process and apparatus for applying it |
US20100010342A1 (en) * | 1999-02-02 | 2010-01-14 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US8626270B2 (en) | 1999-02-02 | 2014-01-07 | Senorx, Inc. | Cavity-filling biopsy site markers |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US20040101479A1 (en) * | 1999-02-02 | 2004-05-27 | Senorx, Inc. | Biopsy site marker and process and apparatus for applying it |
US8219182B2 (en) | 1999-02-02 | 2012-07-10 | Senorx, Inc. | Cavity-filling biopsy site markers |
US20100198059A1 (en) * | 1999-02-02 | 2010-08-05 | Senorx, Inc. | Remotely activated marker |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US7792569B2 (en) | 1999-02-02 | 2010-09-07 | Senorx, Inc. | Cavity-filling biopsy site markers |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US20100324416A1 (en) * | 1999-02-02 | 2010-12-23 | Senorx, Inc. | Cavity-filling biopsy site markers |
US8224424B2 (en) | 1999-02-02 | 2012-07-17 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US8579931B2 (en) | 1999-06-17 | 2013-11-12 | Bard Peripheral Vascular, Inc. | Apparatus for the percutaneous marking of a lesion |
US9579159B2 (en) | 1999-06-17 | 2017-02-28 | Bard Peripheral Vascular, Inc. | Apparatus for the percutaneous marking of a lesion |
US20100298698A1 (en) * | 2000-11-20 | 2010-11-25 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US8718745B2 (en) | 2000-11-20 | 2014-05-06 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US8177792B2 (en) | 2002-06-17 | 2012-05-15 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
US8784433B2 (en) | 2002-06-17 | 2014-07-22 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US20030233101A1 (en) * | 2002-06-17 | 2003-12-18 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US9801688B2 (en) | 2003-05-23 | 2017-10-31 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US20040236213A1 (en) * | 2003-05-23 | 2004-11-25 | Senorx, Inc. | Marker delivery device with releasable plug |
US7970454B2 (en) | 2003-05-23 | 2011-06-28 | Senorx, Inc. | Marker delivery device with releasable plug |
US20090287078A1 (en) * | 2003-05-23 | 2009-11-19 | Senorx, Inc. | Marker or filler forming fluid |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US20040236211A1 (en) * | 2003-05-23 | 2004-11-25 | Senorx, Inc. | Marker or filler forming fluid |
US10045832B2 (en) | 2003-05-23 | 2018-08-14 | Senorx, Inc. | Marker or filler forming fluid |
US8639315B2 (en) | 2003-05-23 | 2014-01-28 | Senorx, Inc. | Marker or filler forming fluid |
US8626269B2 (en) | 2003-05-23 | 2014-01-07 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8880154B2 (en) | 2003-05-23 | 2014-11-04 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US20050119562A1 (en) * | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US8447386B2 (en) | 2003-05-23 | 2013-05-21 | Senorx, Inc. | Marker or filler forming fluid |
US20110092815A1 (en) * | 2003-05-23 | 2011-04-21 | Senorx, Inc. | Marker or filler forming fluid |
US20040236212A1 (en) * | 2003-05-23 | 2004-11-25 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
US10299881B2 (en) | 2003-05-23 | 2019-05-28 | Senorx, Inc. | Marker or filler forming fluid |
US20100298696A1 (en) * | 2003-11-17 | 2010-11-25 | Bard Peripheral Vascular, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US9408592B2 (en) | 2003-12-23 | 2016-08-09 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
US8343071B2 (en) | 2004-12-16 | 2013-01-01 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
US10105125B2 (en) | 2004-12-16 | 2018-10-23 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
US8360990B2 (en) | 2004-12-16 | 2013-01-29 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
US11246574B2 (en) | 2004-12-16 | 2022-02-15 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
US8585663B2 (en) | 2005-03-04 | 2013-11-19 | C. R. Bard, Inc. | Access port identification systems and methods |
US7959615B2 (en) | 2005-03-04 | 2011-06-14 | C. R. Bard, Inc. | Access port identification systems and methods |
US10179230B2 (en) | 2005-03-04 | 2019-01-15 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US8382724B2 (en) | 2005-03-04 | 2013-02-26 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US8382723B2 (en) | 2005-03-04 | 2013-02-26 | C. R. Bard, Inc. | Access port identification systems and methods |
US10238850B2 (en) | 2005-03-04 | 2019-03-26 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US10265512B2 (en) | 2005-03-04 | 2019-04-23 | Bard Peripheral Vascular, Inc. | Implantable access port including a sandwiched radiopaque insert |
US8202259B2 (en) | 2005-03-04 | 2012-06-19 | C. R. Bard, Inc. | Systems and methods for identifying an access port |
US8939947B2 (en) | 2005-03-04 | 2015-01-27 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US20110311337A1 (en) * | 2005-03-04 | 2011-12-22 | C.R. Bard, Inc. | Access port identification systems and methods |
US9682186B2 (en) | 2005-03-04 | 2017-06-20 | C. R. Bard, Inc. | Access port identification systems and methods |
US8029482B2 (en) | 2005-03-04 | 2011-10-04 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US7785302B2 (en) | 2005-03-04 | 2010-08-31 | C. R. Bard, Inc. | Access port identification systems and methods |
US20100268165A1 (en) * | 2005-03-04 | 2010-10-21 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
US9603992B2 (en) | 2005-03-04 | 2017-03-28 | C. R. Bard, Inc. | Access port identification systems and methods |
US10675401B2 (en) | 2005-03-04 | 2020-06-09 | Bard Peripheral Vascular, Inc. | Access port identification systems and methods |
US8603052B2 (en) | 2005-03-04 | 2013-12-10 | C. R. Bard, Inc. | Access port identification systems and methods |
US9603993B2 (en) | 2005-03-04 | 2017-03-28 | C. R. Bard, Inc. | Access port identification systems and methods |
US8998860B2 (en) | 2005-03-04 | 2015-04-07 | C. R. Bard, Inc. | Systems and methods for identifying an access port |
US10857340B2 (en) | 2005-03-04 | 2020-12-08 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US10905868B2 (en) | 2005-03-04 | 2021-02-02 | Bard Peripheral Vascular, Inc. | Systems and methods for radiographically identifying an access port |
US9474888B2 (en) | 2005-03-04 | 2016-10-25 | C. R. Bard, Inc. | Implantable access port including a sandwiched radiopaque insert |
US11077291B2 (en) | 2005-03-04 | 2021-08-03 | Bard Peripheral Vascular, Inc. | Implantable access port including a sandwiched radiopaque insert |
US20080140025A1 (en) * | 2005-03-04 | 2008-06-12 | C. R. Bard, Inc. | Access port identification systems and methods |
US7947022B2 (en) | 2005-03-04 | 2011-05-24 | C. R. Bard, Inc. | Access port identification systems and methods |
US20060241411A1 (en) * | 2005-04-20 | 2006-10-26 | Inrad, Inc. | Marking device with retracable cannula |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
US8545460B2 (en) | 2005-04-27 | 2013-10-01 | C. R. Bard, Inc. | Infusion apparatuses and related methods |
US10661068B2 (en) | 2005-04-27 | 2020-05-26 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US8805478B2 (en) | 2005-04-27 | 2014-08-12 | C. R. Bard, Inc. | Methods of performing a power injection procedure including identifying features of a subcutaneously implanted access port for delivery of contrast media |
US10016585B2 (en) | 2005-04-27 | 2018-07-10 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US10052470B2 (en) | 2005-04-27 | 2018-08-21 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US8475417B2 (en) | 2005-04-27 | 2013-07-02 | C. R. Bard, Inc. | Assemblies for identifying a power injectable access port |
US10183157B2 (en) | 2005-04-27 | 2019-01-22 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US10307581B2 (en) | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
US10625065B2 (en) | 2005-04-27 | 2020-04-21 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US8641688B2 (en) | 2005-04-27 | 2014-02-04 | C. R. Bard, Inc. | Assemblies for identifying a power injectable access port |
US8641676B2 (en) | 2005-04-27 | 2014-02-04 | C. R. Bard, Inc. | Infusion apparatuses and methods of use |
US10780257B2 (en) | 2005-04-27 | 2020-09-22 | Bard Peripheral Vascular, Inc. | Assemblies for identifying a power injectable access port |
US9421352B2 (en) | 2005-04-27 | 2016-08-23 | C. R. Bard, Inc. | Infusion apparatuses and methods of use |
US9937337B2 (en) | 2005-04-27 | 2018-04-10 | C. R. Bard, Inc. | Assemblies for identifying a power injectable access port |
US8025639B2 (en) | 2005-04-27 | 2011-09-27 | C. R. Bard, Inc. | Methods of power injecting a fluid through an access port |
US10478161B2 (en) | 2005-05-23 | 2019-11-19 | Senorx, Inc. | Tissue cutting member for a biopsy device |
US8641640B2 (en) | 2005-05-23 | 2014-02-04 | Senorx, Inc. | Tissue cutting member for a biopsy device |
US11426149B2 (en) | 2005-05-23 | 2022-08-30 | SenoRx., Inc. | Tissue cutting member for a biopsy device |
US9750487B2 (en) | 2005-05-23 | 2017-09-05 | Senorx, Inc. | Tissue cutting member for a biopsy device |
US9095325B2 (en) | 2005-05-23 | 2015-08-04 | Senorx, Inc. | Tissue cutting member for a biopsy device |
US7981051B2 (en) | 2005-08-05 | 2011-07-19 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US10874381B2 (en) | 2005-08-05 | 2020-12-29 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US8915864B2 (en) | 2005-08-05 | 2014-12-23 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US8317725B2 (en) | 2005-08-05 | 2012-11-27 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US7572236B2 (en) | 2005-08-05 | 2009-08-11 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US10064609B2 (en) | 2005-08-05 | 2018-09-04 | Senorx, Inc. | Method of collecting one or more tissue specimens |
US8486028B2 (en) | 2005-10-07 | 2013-07-16 | Bard Peripheral Vascular, Inc. | Tissue marking apparatus having drug-eluting tissue marker |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
US20110184449A1 (en) * | 2006-08-04 | 2011-07-28 | Senorx, Inc. | Marker delivery device with obturator |
US20090171198A1 (en) * | 2006-08-04 | 2009-07-02 | Jones Michael L | Powdered marker |
US20080058640A1 (en) * | 2006-08-04 | 2008-03-06 | Senoxrx, Inc. | Marker formed of starch or other suitable polysaccharide |
US11878137B2 (en) | 2006-10-18 | 2024-01-23 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US8437834B2 (en) | 2006-10-23 | 2013-05-07 | C. R. Bard, Inc. | Breast marker |
US20080108949A1 (en) * | 2006-11-08 | 2008-05-08 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US10092725B2 (en) | 2006-11-08 | 2018-10-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US10556090B2 (en) | 2006-11-08 | 2020-02-11 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US9265912B2 (en) | 2006-11-08 | 2016-02-23 | C. R. Bard, Inc. | Indicia informative of characteristics of insertable medical devices |
US10682200B2 (en) | 2006-12-12 | 2020-06-16 | C. R. Bard, Inc. | Multiple imaging mode tissue marker |
US20100030072A1 (en) * | 2006-12-12 | 2010-02-04 | Casanova R Michael | Multiple Imaging Mode Tissue Marker |
US9901415B2 (en) | 2006-12-12 | 2018-02-27 | C. R. Bard, Inc. | Multiple imaging mode tissue marker |
US11471244B2 (en) | 2006-12-12 | 2022-10-18 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
US9579077B2 (en) | 2006-12-12 | 2017-02-28 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
US8401622B2 (en) | 2006-12-18 | 2013-03-19 | C. R. Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US20100010341A1 (en) * | 2006-12-18 | 2010-01-14 | Talpade Dnyanesh A | Biopsy Marker with In Situ-Generated Imaging Properties |
US9042965B2 (en) | 2006-12-18 | 2015-05-26 | C. R. Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US8852160B2 (en) | 2007-06-20 | 2014-10-07 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US9533133B2 (en) | 2007-06-20 | 2017-01-03 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US11478622B2 (en) | 2007-06-20 | 2022-10-25 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US8257325B2 (en) | 2007-06-20 | 2012-09-04 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US11406808B2 (en) | 2007-06-20 | 2022-08-09 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
US10874842B2 (en) | 2007-07-19 | 2020-12-29 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US10639465B2 (en) | 2007-07-19 | 2020-05-05 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
US8021324B2 (en) | 2007-07-19 | 2011-09-20 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US9610432B2 (en) | 2007-07-19 | 2017-04-04 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
US11547843B2 (en) | 2007-07-19 | 2023-01-10 | Innovative Medical Devices, Llc | Venous access port assembly with x-ray discernable indicia |
US9517329B2 (en) | 2007-07-19 | 2016-12-13 | Medical Components, Inc. | Venous access port assembly with X-ray discernable indicia |
US20090156928A1 (en) * | 2007-11-07 | 2009-06-18 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US10086186B2 (en) | 2007-11-07 | 2018-10-02 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US10792485B2 (en) | 2007-11-07 | 2020-10-06 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US9579496B2 (en) | 2007-11-07 | 2017-02-28 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US11638810B2 (en) | 2007-11-07 | 2023-05-02 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US8311610B2 (en) | 2008-01-31 | 2012-11-13 | C. R. Bard, Inc. | Biopsy tissue marker |
US20100331668A1 (en) * | 2008-01-31 | 2010-12-30 | Ranpura Himanshu M | Biopsy Tissue Marker |
US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
US11833275B2 (en) | 2008-09-23 | 2023-12-05 | Senorx, Inc. | Porous bioabsorbable implant |
US20100082102A1 (en) * | 2008-09-23 | 2010-04-01 | Senorx, Inc. | Porous bioabsorbable implant |
US10786604B2 (en) | 2008-09-23 | 2020-09-29 | Senorx, Inc. | Porous bioabsorbable implant |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US11890443B2 (en) | 2008-11-13 | 2024-02-06 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US10773066B2 (en) | 2008-11-13 | 2020-09-15 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US10052471B2 (en) | 2008-11-13 | 2018-08-21 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US11779431B2 (en) | 2008-12-30 | 2023-10-10 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US8670818B2 (en) | 2008-12-30 | 2014-03-11 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US10258428B2 (en) | 2008-12-30 | 2019-04-16 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US20110028836A1 (en) * | 2008-12-30 | 2011-02-03 | Himanshu Ranpura | Marker delivery device for tissue marker placement |
US20110009828A1 (en) * | 2009-07-07 | 2011-01-13 | C.R.Bard, Inc. | Extensible internal bolster for a medical device |
US8715244B2 (en) | 2009-07-07 | 2014-05-06 | C. R. Bard, Inc. | Extensible internal bolster for a medical device |
US10926075B2 (en) | 2009-10-16 | 2021-02-23 | Smiths Medical Asd, Inc. | Portal with septum embedded indicia |
US9950150B2 (en) | 2009-10-16 | 2018-04-24 | Smiths Medical Asd, Inc. | Portal with septum embedded indicia |
US10912935B2 (en) | 2009-11-17 | 2021-02-09 | Bard Peripheral Vascular, Inc. | Method for manufacturing a power-injectable access port |
US9717895B2 (en) | 2009-11-17 | 2017-08-01 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US20110118677A1 (en) * | 2009-11-17 | 2011-05-19 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US11759615B2 (en) | 2009-11-17 | 2023-09-19 | Bard Peripheral Vascular, Inc. | Overmolded access port including anchoring and identification features |
US10155101B2 (en) | 2009-11-17 | 2018-12-18 | Bard Peripheral Vascular, Inc. | Overmolded access port including anchoring and identification features |
US9079004B2 (en) | 2009-11-17 | 2015-07-14 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
US9248268B2 (en) | 2009-11-17 | 2016-02-02 | C. R. Bard, Inc. | Overmolded access port including anchoring and identification features |
USD676955S1 (en) | 2010-12-30 | 2013-02-26 | C. R. Bard, Inc. | Implantable access port |
USD682416S1 (en) | 2010-12-30 | 2013-05-14 | C. R. Bard, Inc. | Implantable access port |
US10145856B2 (en) * | 2017-03-22 | 2018-12-04 | Hall Labs, Llc | Drug tracking system including food dyes detectable in bodily waste |
US9927448B1 (en) * | 2017-03-22 | 2018-03-27 | David R. Hall | Method of measuring food dyes in bodily waste to identify and quantify drug consumption |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3341417A (en) | Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators | |
Hens et al. | Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities | |
Strong et al. | Equal aspiration rates from postpylorus and intragastric‐placed small‐bore nasoenteric feeding tubes: a randomized, prospective study | |
Alvarez et al. | The rate of progress of food residues through the bowel | |
US20060235312A1 (en) | Combination and method including a visual marker for determining compliance with a medication regimen | |
Wilson et al. | Assessment of disintegration and dissolution of dosage forms in vivo using gamma scintigraphy | |
Jenis et al. | Acute meprobamate poisoning: a fatal case following a lucid interval | |
Leonards | Absence of gastrointestinal bleeding following administration of salicylsalicylic acid | |
Berk et al. | Intra-abdominal chicken-bone abscess | |
Chan et al. | Poisoning due to Chinese proprietary medicines | |
Cole | The development of cholecystography: the first fifty years | |
Aki et al. | General approach to poisoned patient | |
Fantus et al. | Phenolphthalein studies: a thousand doses of phenolphthalein: urinalyses | |
Fisher et al. | Iodoquinol associated seizures and radiopacity | |
Chan et al. | The clinical value of screening for paracetamol in patients with acute poisoning | |
RU2620162C1 (en) | X-ray-contrast marker for chronic constipation diagnostics and capsule with x-ray contrast markers | |
Gavala et al. | Methadone gastrobezoar in a psychiatric patient presented in coma | |
Bagchi | Incidence of lead poisoning among Hindu women and children | |
Dillard | Jejunal Sensitivity to Acid Peptic Digestion | |
BL | QP D PHARM ANNUAL 2021 | |
Menees et al. | Oral administration of tetraiodophenolphthalein for cholecystography | |
SU1454392A1 (en) | Method of diagnosis of mechanical ileus of small intestines | |
Mather et al. | Cholecystography: the results of 125 consecutive cases examined by the oral administration of the salt | |
Lovejoy Jr et al. | Poisoning in children under age 5: Identification and treatment | |
Caldwell et al. | The influence of phenolphthalein on intestinal movements |